Navigation Links
Diabetes slows nerve recovery after heart transplant

Diabetes has a detrimental effect on a person's ability to recover from a heart transplant, notes a study in the September Journal of Nuclear Medicine.

"Using positron emission tomography (PET) and the transplanted heart as a very specific model to study the regenerative capacity of the heart's sympathetic nervous system, we determined that reinnervation--or the heart's ability to develop new nerves to replace damaged ones--is slower in diabetic patients," said Frank M. Bengel, a visiting associate professor of radiology and the director of cardiovascular nuclear medicine at Johns Hopkins Medicine's Russell H. Morgan Department of Radiology and Radiological Science in Baltimore, Md. "Our results confirm a detrimental effect of diabetes on the potential for recovery of sympathetic nerve fibers of the heart," added the co-author of "Effect of Diabetes Mellitus on Sympathetic Neuronal Regeneration Studied in the Model of Transplant Reinnervation."

"A better understanding of the importance of nervous system abnormalities and an imaging technique to precisely characterize nerve damage may be of value to guide future therapeutic efforts aimed at reducing cardiac risk with diabetes mellitus patients," explained Bengel, who was an associate professor at the Technical University of Munich, where the study was performed, prior to his move to Johns Hopkins. "Even if a transplant recipient is suffering from diabetes, there is still a chance for reinnervation--just at a slower speed," he added. "Unfortunately, there are no techniques developed yet that speed the nerve regeneration process," he said.

Currently, nuclear medicine techniques (such as PET) are the only imaging techniques that can measure the presence and function of the sympathetic nervous system of the heart, said Bengel. "There are invasive methods that allow for the measurement of neurotransmitters released to the blood, offering indirect conclusions about the presence, storage and releas
'"/>

Source:Society of Nuclear Medicine


Page: 1 2

Related biology news :

1. FDA Approves New Drug to Treat Type I and Type II Diabetes
2. First North American Encapsulated Islet Transplant without Long-term Immune Suppression into a Patient with Type 1 Diabetes
3. Single-donor Islet Transplantation Procedure Shows Promise For Patients With Type 1 Diabetes
4. Precise Timing Enabled Pig-to-rat Transplants To Cure Diabetes
5. Diabetes researchers pioneer islet cell xenotransplantation in primate studies
6. Diabetes hits 275 Australians each day as pandemic spreads
7. Diabetes research takes wing thanks to long-lived fruit fly
8. Cancer drug slows poxvirus in mice
9. Stress substantially slows human bodys ability to heal
10. Cell therapy slows progression of an inherited neurological disease; Improves motor skills in mice
11. Protein found that slows hepatitis C growth in liver cells

Post Your Comments:
(Date:11/9/2009)...led phytoplankton are flourishing in areas of open...g of ice shelves and glaciers around the Antarctic... a beneficial impact on climate change. As the blo...ere it can store carbon for thousands or millions ... Global Change Biology , scientists from British A...
(Date:11/9/2009)...s David Queller and Joan Strassmann argue in a new...een components, from the genetic level on up, give...thing is an animal, a plant, a bacteria or a colo...ibe an organism, such as individuality or even mem...to achieve organismality. What is necessary, they ...
(Date:11/9/2009)...ire/ -- Genencor, a division of Danisco, has won t...erican Institute of Chemical Engineers (AIChE) for...losic ethanol. Yesterday, Robert Davis, Chair of t...Landon Steele, who is Marketing Director, Biomass ... Aaron Kelley, who is Senior Engineer, Biomass App...
Breaking Biology News(10 mins):Antarctica glacier retreat creates new carbon dioxide store 2What is the meaning of 'one'? 2What is the meaning of 'one'? 3Genencor Wins The American Institute of Chemical Engineers (AIChE) Sustainable Energy Award For Accellerase(R) Cellulosic Ethanol Enzymes 2UD to host conference on Ethics of Climate Change 10413 1UD to host conference on Ethics of Climate Change 10413 2CDPHP Launches National Network and Three In One Plan and Expands Member Incentives 59754 1CDPHP Launches National Network and Three In One Plan and Expands Member Incentives 59754 2CDPHP Launches National Network and Three In One Plan and Expands Member Incentives 59754 3CDPHP Launches National Network and Three In One Plan and Expands Member Incentives 59754 4Scientists Find New Key to Lupus 59752 1Scientists Find New Key to Lupus 59752 2
...izes and shapes, making them the perfect subject t...er is "rapidly becoming the standard for fruit mor...y led by Marin Talbot Brewer of The Ohio State Uni...nce. Details of the team,s latest Tomato Analyzer ...Journal of the American Society for Horticultural ...
...dustry has been growing rapidly since the mid-1980...onomy annually. Examples of nontimber forest produ..., medicinal and herbal products, and specialty flo... industry include U.S.-grown herbs used to satisfy.... American ginseng, for example, accounted for $32...
...chers have identified a new anticonvulsant compoun...f epilepsy. The findings are published in the Marc...arch discovery builds on previous work identifying...vity is associated with seizure disorders, a potas... found a new anticonvulsant compound that eliminat...
Other Biology News:New and improved tomato analyzer 2Decreasing deer damage 2Decreasing deer damage 3Drug prevents seizure progression in model of epilepsy 2
(Date:11/6/2009)...rstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP"...ocherty, president and chief operating officer, wi...vestor Summit on November 10, 2009 at 4:00 PM at t...ill provide an overview of the Company,s leading p...terferon Alpha-2b. The slide show portion of the ...
(Date:11/6/2009)...FirstCall/ -- ,, 3Q09 Corporate Highlights: ...rketing Authorization to Astellas Pharma Europe Lt...ness activities Expanded management team to inclu...tor, Commercial Operations Appointed Bradford S. ...hairman , Upcoming 2009 Milestones: ,,...
(Date:11/6/2009)...- Intarcia Therapeutics, Inc. delivered two presen...ous delivery of exenatide) program for the treatme... Technology Meeting in San Francisco, CA: ,, (L.../SFTU126LOGO ) ,, Continuous Subcutaneous Del...ose, HbA1c and Reduces Weight in a 28-day Phase 1b...
(Date:11/5/2009)...FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC ) today ...ter ended September 30, 2009. GenVec reported a ne...hree months ended September 30, 2009 compared to a... comparable quarter of 2008. For the nine months e....1 million ($0.15 per share), compared to a net lo...
Breaking Biology Technology:Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6
... Phase 2 Switching Study, CRANBURY, N.J., March 1...y developing small-molecule, orally administered,p...an genetic diseases,announced today that the Compa...inical study of Plicera(TM) (isofagomine tartrate)...dical Genetics (ACMG) Annual Meeting from,March 12...
...lished online today in Genome Research ( www.gen...ry conservation of the genes and pathways associat...cation of conserved aging-related genes in simple ...ion of similar genes playing a role in human aging...organisms experience aging, the underlying mechani...
...ar Net Income up 283.0%, SHANGHAI, China, March 1... (Cayman) Inc. (NYSE: WX ), the leading global ph...outsourcing company headquartered in,Shanghai, Chi...s for the,fourth quarter and full year ended Decem... Compared to the fourth quarter 2006 results, -- ...
Other Biology Technology:Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease 2Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease 3Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease 4Growing old together: Yeast, worms and people may age by similar mechanisms 2WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 2WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 4WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 5WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 6WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 7WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 8WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 9WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 10WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 11WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 12
Rabbit Anti-Mouse Junctophilin-4, C-Terminus Monoclonal Antibody, Unconjugated, Clone PADZMD.487 from Invitrogen
...PCR Cloning Kits are designed to speed up the PCR ...s, regardless of sequence or type of polymerase us...ding those that are difficult to clone by other PC...for potentially detrimental proteins can be cloned...
Mounting Medium from BioVision
GeneAmp High Fidelity PCR from Applied Biosystems
Biology Products: